Puma Biotechnology
PBYI
136 hedge funds and large institutions have $1.41B invested in Puma Biotechnology in 2017 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 45 increasing their positions, 32 reducing their positions, and 19 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
84% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 19
41% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 32
32% more capital invested
Capital invested by funds: $1.07B → $1.41B (+$340M)
7.87% more ownership
Funds ownership: 94.87% → 102.74% (+7.9%)
6% more funds holding
Funds holding: 128 → 136 (+8)
9% less call options, than puts
Call options by funds: $16.8M | Put options by funds: $18.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$63.4M |
| 2 |
PC
PointState Capital
New York
|
+$28.1M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$23.7M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$21.2M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$17.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
-$33.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$16.3M |
| 3 |
Morgan Stanley
New York
|
-$16.2M |
| 4 |
Citigroup
New York
|
-$5.22M |
| 5 |
JP
Jana Partners
New York
|
-$4.38M |
PBYI Hedge Fund Activity: Q1 2017 in Review
136 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q1 2017, worth a combined $1.41B — up 32% from $1.07B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new PBYI positions and 19 closed out — a net gain of 16 holders — while 45 added to existing stakes and 32 trimmed.
The largest buyer was BlackRock, adding an estimated $63.4M. The largest seller was American Century Companies, cutting an estimated $33.7M.
- 136 institutional investors held Puma Biotechnology (PBYI) as of Q1 2017, up from 128 in Q4 2016.
- Funds reported $1.41B of Puma Biotechnology stock for Q1 2017, up 32% quarter-over-quarter.
- 35 funds opened new Puma Biotechnology positions in Q1 2017 and 19 closed out, a net change of +16 holders.
- The largest Puma Biotechnology buyer in Q1 2017 was BlackRock, an estimated $63.4M added.
- The largest Puma Biotechnology seller in Q1 2017 was American Century Companies, an estimated $33.7M sold.
Based on aggregated 13F filings for Q1 2017.